Genescience discovers new SLC6A19 inhibitors for PKU
Oct. 29, 2025
Genescience Pharmaceuticals Co. Ltd. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria (PKU).